These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 14401152)

  • 1. [Behavior of the blood sedimentation reaction in glioma].
    HENSELL V
    Acta Neurochir Suppl (Wien); 1959; 6():230-4. PubMed ID: 14401152
    [No Abstract]   [Full Text] [Related]  

  • 2. [Erythrocyte sedimentation rate in intracranial supratentorial].
    Turowski K; Markiewicz P
    Wiad Lek; 1982 Apr; 35(2):115-8. PubMed ID: 7101928
    [No Abstract]   [Full Text] [Related]  

  • 3. [On the blood sedimentation reaction modified by Gross. Findings in neurosurgical diseases].
    Goldhahn G
    Psychiatr Neurol Med Psychol (Leipz); 1968 Sep; 20(9):342-8. PubMed ID: 5731890
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of erythrocyte sedimentation rate and C-reactive protein in the blood of patients with glioma.
    Strojnik T; Smigoc T; Lah TT
    Anticancer Res; 2014 Jan; 34(1):339-47. PubMed ID: 24403485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophoretic analysis of proteins in sera of patients with central nervous system tumors.
    Apuzzo ML; Sheikh KM; Davis R; Heiden JS; Weiss MH
    Surg Forum; 1979; 30():437-9. PubMed ID: 538659
    [No Abstract]   [Full Text] [Related]  

  • 6. ABO blood group and risk of glioma.
    Cote DJ; Downer MK; Zoltick ES; Smith TR; Stampfer MJ
    Neuro Oncol; 2017 Jun; 19(6):871-873. PubMed ID: 28339823
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of ABO blood group system to intracranial tumours--a study from South India.
    Sundar P; Malini AV; Radha RK; Sangeetha SK; Subba Krishna DK; Shankar SK
    Indian J Pathol Microbiol; 2006 Jul; 49(3):473-5. PubMed ID: 17001929
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibrin degradation products, produced by glioma cell-associated fibrinolysis and the partial inhibition of cell growth and migration in tissue culture.
    Zänker KS; Stavrou D; Blümel G
    Cell Mol Biol Incl Cyto Enzymol; 1979; 25(6):387-94. PubMed ID: 575505
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum microRNAs as potential noninvasive biomarkers for glioma.
    Yu X; Li Z
    Tumour Biol; 2016 Feb; 37(2):1407-10. PubMed ID: 26628296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Specific cerebral alpha 1-globulin in glial tumors].
    Obukhov SK
    Zh Vopr Neirokhir Im N N Burdenko; 1985; (4):43-7. PubMed ID: 2413665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive meta-analysis of circulation miRNAs in glioma as potential diagnostic biomarker.
    Ma C; Nguyen HPT; Luwor RB; Stylli SS; Gogos A; Paradiso L; Kaye AH; Morokoff AP
    PLoS One; 2018; 13(2):e0189452. PubMed ID: 29444091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of blood-tumor barrier permeability by Sar-[D-Phe8]des-Arg9BK, a metabolically resistant bradykinin B1 agonist, in a rat C6 glioma model.
    Cardoso RC; Lobão-Soares B; Bianchin MM; Carlotti CG; Walz R; Alvarez-Silva M; Trentin AG; Nicolau M
    BMC Neurosci; 2004 Sep; 5():38. PubMed ID: 15458573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Measurement of blood polyamines in patients with brain tumor--special reference to relationship between the blood levels of spermidine and spermine, and histological malignancy in patients with glioma (author's transl)].
    Terabayashi T
    No To Shinkei; 1977 Nov; 29(11):1215-20. PubMed ID: 337979
    [No Abstract]   [Full Text] [Related]  

  • 14. [The morphology of hemostasis failure in gliosal brain tumors].
    Engel U
    Acta Histochem Suppl; 1992; 42():201-10. PubMed ID: 1584966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients.
    García-Romero N; Carrión-Navarro J; Esteban-Rubio S; Lázaro-Ibáñez E; Peris-Celda M; Alonso MM; Guzmán-De-Villoria J; Fernández-Carballal C; de Mendivil AO; García-Duque S; Escobedo-Lucea C; Prat-Acín R; Belda-Iniesta C; Ayuso-Sacido A
    Oncotarget; 2017 Jan; 8(1):1416-1428. PubMed ID: 27902458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum granulocyte colony-stimulating factor levels in gliomas.
    Yildiz R; Coskun U; Buyukberber S; Sancak B; Kaya AO; Gulbahar O; Benekli M
    J BUON; 2011; 16(1):138-41. PubMed ID: 21674865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood levels of polyamines in patients with brain tumor: special reference to relationship between blood levels of polyamines and histological finding, extension as well as treatment of tumor;
    Terabyashi T
    Neurol Med Chir (Tokyo); 1976; 16(PT1):43-50. PubMed ID: 66639
    [No Abstract]   [Full Text] [Related]  

  • 19. Glioma risk in relation to serum levels of insulin-like growth factors.
    Lönn S; Inskip PD; Pollak MN; Weinstein SJ; Virtamo J; Albanes D
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):844-6. PubMed ID: 17416782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of fibrin degradation products in glioma and meningioma patients.
    Can O; Erdemgil Y; Yildirim ZZ; Ozduman K; Pamir MN; Sav A; Ozpinar A
    Cancer Biomark; 2014; 14(4):253-8. PubMed ID: 24934368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.